343 related articles for article (PubMed ID: 19112805)
21. Correction options for lipoatrophy in HIV-infected patients.
Engelhard P
AIDS Patient Care STDS; 2006 Mar; 20(3):151-60. PubMed ID: 16548712
[TBL] [Abstract][Full Text] [Related]
22. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
[TBL] [Abstract][Full Text] [Related]
23. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires.
Warde M; Gragnani A; Gomes H; Hochman B; Ferreira LM
Int J STD AIDS; 2011 Oct; 22(10):596-9. PubMed ID: 21998182
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler.
Rauso R; Curinga G; Rusciani A; Colella G; Amore R; Tartaro G
Dermatol Surg; 2013 Dec; 39(12):1887-94. PubMed ID: 24299576
[TBL] [Abstract][Full Text] [Related]
25. HIV-associated facial lipoatrophy--review of current therapy options.
Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
[TBL] [Abstract][Full Text] [Related]
26. Treatment of facial lipoatrophy in HIV-infected patients.
Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
[TBL] [Abstract][Full Text] [Related]
27. Patient Reported Outcomes from HIV Facial Lipoatrophy Treatment With a Volumizing Hyaluronic Acid Filler: A Prospective, Open-Label, Phase I and II Study.
Ho D; Jagdeo J
J Drugs Dermatol; 2016 Sep; 15(9):1064-9. PubMed ID: 27602967
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of a Volumizing Hyaluronic Acid Filler for Treatment of HIV-Associated Facial Lipoatrophy.
Ho D; Jagdeo J
JAMA Dermatol; 2017 Jan; 153(1):61-65. PubMed ID: 27806168
[TBL] [Abstract][Full Text] [Related]
29. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy.
Pignatti M; Pedone A; Baccarani A; Guaraldi G; Orlando G; Lombardi M; De Santis G
Aesthetic Plast Surg; 2012 Feb; 36(1):180-5. PubMed ID: 21717261
[TBL] [Abstract][Full Text] [Related]
30. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
Hartman K; Verweel G; de Groot R; Hartwig NG
Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
[TBL] [Abstract][Full Text] [Related]
31. Restorative interventions for HIV facial lipoatrophy.
Carey D; Liew S; Emery S
AIDS Rev; 2008; 10(2):116-24. PubMed ID: 18615122
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of injectable CaHA for the treatment of mid-face volume loss.
Beer K; Yohn M; Cohen JL
J Drugs Dermatol; 2008 Apr; 7(4):359-66. PubMed ID: 18459517
[TBL] [Abstract][Full Text] [Related]
33. Cost consequences of HIV-associated lipoatrophy.
Hornberger J; Rajagopalan R; Shewade A; Loutfy MR
AIDS Care; 2009 May; 21(5):664-71. PubMed ID: 19444676
[TBL] [Abstract][Full Text] [Related]
34. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
Phillips DR; Hay P
J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
[TBL] [Abstract][Full Text] [Related]
35. Relationship between lipoatrophy and quality of life.
Echavez M; Horstman W
AIDS Read; 2005 Jul; 15(7):369-75. PubMed ID: 16044579
[TBL] [Abstract][Full Text] [Related]
36. Contemporary surgical management of HIV-associated facial lipoatrophy.
Funk E; Bressler FJ; Brissett AE
Otolaryngol Head Neck Surg; 2006 Jun; 134(6):1015-22. PubMed ID: 16730549
[TBL] [Abstract][Full Text] [Related]
37. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
Parruti G; Toro GM
BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
[TBL] [Abstract][Full Text] [Related]
38. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
[TBL] [Abstract][Full Text] [Related]
39. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA).
Jagdeo J; Ho D; Lo A; Carruthers A
J Am Acad Dermatol; 2015 Dec; 73(6):1040-54.e14. PubMed ID: 26481056
[TBL] [Abstract][Full Text] [Related]
40. Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy.
Nadarajah JT; Collins M; Raboud J; Su D; Rao K; Loutfy MR; Walmsley S
Clin Infect Dis; 2012 Dec; 55(11):1568-74. PubMed ID: 22942210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
